Abstract
Background: Olaparib, the world's first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
